In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, the ACAAI requires that all individuals in a position to control or influence the content of an activity disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients.

All identified relevant financial relationships with ineligible companies have been mitigated.
Sudhir Gupta, MD – No financial relationships to disclose.
Chris Chang, MD, PhD, MBA – No financial relationships to disclose.
Sarah E. Henrickson, MD, PhD – No financial relationships to disclose.
Hal Hoffman, MD – Consultant: Amgen, Novartis, Pharming Group, Sobi, Zomagen; Speaker: Amgen

Disclaimer

The content of this activity was developed independently of any ineligible companies. The opinions expressed are those of the faculty and do not necessarily reflect the opinions of the ACAAI.

This activity was planned in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. The educational content was reviewed for content validity to ensure that it is evidence-based, balanced, scientifically objective, and free of commercial bias.

Unapproved Uses of Drugs and Devices: This CME/CE activity may include discussion of investigational, off-label, or unapproved uses of drugs and/or devices. Please refer to the FDA-approved prescribing information for each drug or device for complete information regarding approved uses and prescribing recommendations.